1. Home
  2. RA vs CSTL Comparison

RA vs CSTL Comparison

Compare RA & CSTL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

Logo Brookfield Real Assets Income Fund Inc.

RA

Brookfield Real Assets Income Fund Inc.

HOLD

Current Price

$12.73

Market Cap

741.0M

Sector

Finance

ML Signal

HOLD

Logo Castle Biosciences Inc.

CSTL

Castle Biosciences Inc.

HOLD

Current Price

$25.38

Market Cap

806.3M

Sector

Health Care

ML Signal

HOLD

Company Overview

Basic Information
Metric
RA
CSTL
Founded
N/A
2007
Country
United States
United States
Employees
N/A
N/A
Industry
Investment Managers
Medical Specialities
Sector
Finance
Health Care
Exchange
Nasdaq
Nasdaq
Market Cap
741.0M
806.3M
IPO Year
2016
2019

Fundamental Metrics

Financial Performance
Metric
RA
CSTL
Price
$12.73
$25.38
Analyst Decision
Strong Buy
Analyst Count
0
6
Target Price
N/A
$47.17
AVG Volume (30 Days)
208.4K
397.3K
Earning Date
01-01-0001
05-18-2026
Dividend Yield
N/A
N/A
EPS Growth
N/A
N/A
EPS
N/A
N/A
Revenue
N/A
$344,229,000.00
Revenue This Year
N/A
$2.10
Revenue Next Year
N/A
$12.63
P/E Ratio
N/A
N/A
Revenue Growth
N/A
3.66
52 Week Low
$11.87
$14.59
52 Week High
$13.59
$44.28

Technical Indicators

Market Signals
Indicator
RA
CSTL
Relative Strength Index (RSI) 28.07 26.28
Support Level N/A $21.77
Resistance Level $13.02 $34.97
Average True Range (ATR) 0.15 1.38
MACD -0.09 -0.09
Stochastic Oscillator 1.22 7.96

Price Performance

Historical Comparison
RA
CSTL

About RA Brookfield Real Assets Income Fund Inc.

Brookfield Real Assets Income Fund Inc. is a diversified, closed-end management investment company. Its investment objective is to seek a high total return, through high current income and secondarily, through the growth of capital. The Fund seeks to achieve its investment objective by investing in the real asset class, which includes the following: Real Estate Securities; Infrastructure Securities; and Natural Resources Securities. The Firm manages separate accounts, registered funds, and opportunistic strategies for institutional and individual clients, including financial institutions, public and private pension plans, insurance companies, endowments and foundations, sovereign wealth funds, and high-net-worth investors.

About CSTL Castle Biosciences Inc.

Castle Biosciences Inc is a molecular diagnostics company. The group provides test solutions for the diagnosis and treatment of dermatologic cancers, Barrett's esophagus (BE), and uveal melanoma. The product portfolio of the company includes DecisionDx-Melanoma, a risk stratification gene expression profile (GEP) test; DecisionDx-SCC, a risk stratification test for cutaneous squamous cell carcinoma; MyPath Melanoma, a diagnostic GEP test for use in patients with difficult-to-diagnose melanocytic lesions; and TissueCypher, a test to predict future development of progression of high-grade dysplasia and/or esophageal cancer. The company derives revenues through the delivery of test reports for its molecular diagnostic tests.

Share on Social Networks: